Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 1 ... Sepracor's currently marketed products in the U.S. include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand ...
2009 SEP 14 ... disorders. Sepracor's currently marketed products in the U.S. include LUNESTA® (eszopiclone) for the treatment of insomnia in adults, XOPENEX® (levalbuterol HCl) Inhalation ...
2009 APR 6 ... Inc. in the U.S. District Court of New Jersey in connection with the ANDA filing for Eszopiclone Tablets, 1 mg, 2 mg and 3 mg. Eszopiclone Tablets are ...
2009 JUL 20 ... the United States conducted a study "To assess the cost-effectiveness of treatment with eszopiclone for chronic primary insomnia in adults. A model using patient-level data from a 6-month, ...
2009 MAR 30 ... and central nervous system disorders. Currently marketed products include LUNESTA® brand eszopiclone, XOPENEX® brand levalbuterol HCl Inhalation Solution, XOPENEX HFA® brand levalbuterol ...
2009 APR 6 ... new drug applications (ANDAs) with Paragraph IV certifications for generic copies of eszopiclone. Sepracor markets eszopiclone in the U.S. under the ...
2009 AUG 3 ... license revenue accelerated as a result of the termination of the LUNIVIA® (eszopiclone) agreement with GlaxoSmithKline (GSK). GAAP net income for the three months ended June ...
2009 MAR 16 ... evaluating the efficacy and safety of SEP-225441, a modified-release formulation of eszopiclone for the treatment of generalized anxiety disorder (GAD). Sepracor determined that the ...
2009 NOV 9 ... a need for more clarification of these risks. Because of preliminary suggestions that eszopiclone causes infections, we studied US Food and Drug Administration files on the 4 ...
2009 NOV 2 ... a randomized, placebo-controlled clinical trial evaluating the long-term efficacy of eszopiclone for primary insomnia (N=828)." "Logistic regression models were used to ...
2008 NOV 24 ... medical writing. During this time, he served as the medical director for the Lunesta(R) (eszopiclone) development program and helped establish partnerships for this product in the EU with ...
2008 NOV 10 ... a positive opinion recommending to grant a marketing authorization for LUNIVIA(R) brand eszopiclone in the European Union (EU) for the treatment of insomnia. The EU labeling provides for ...
2008 OCT 27 ... Keywords: Research and Markets, Ambien, Drugs, Eszopiclone, Hypnotics and Sedatives, Lunesta, Pharmaceutical Business, Pharmaceutical Company, ...
2008 NOV 3 ... and Drug Administration (FDA) Approval History and Documents were accessed for zaleplon, eszopiclone and ramelteon. Since zolpidem was used as a comparison drug in zaleplon trials, some ...
2008 NOV 10 ... performance and enhanced shareholder value over time."
LUNESTA(R) brand eszopiclone, for the treatment of insomnia, generated revenues of $154.7 million in the third ...
